Kornimate/medical-research-clean huggingface dataset:
prevalence of primary aldosteronism in young adults with acute stroke

Conditions: Primary Aldosteronism

Summary: the guideline requires clinical works to screen for primary aldosteronism(pa) in young adults with family history of stroke at early onset. but the prevalence of pa in young adults with stroke onset before 45 years old had never been investigated. the study aimed to discover the prevalence as well as the clinical characteristics between patients with pa and those without pa during stroke attack. in order to fulfill this objective, investigators intended to conduct a cross-sectional study by taking screening and confirmatory tests among young adults who once admitted due to early onset of acute stroke.


Eligibility criteria:
inclusion criteria: - patients who were once admitted in the first affiliated hospital of chongqing medical university(cqmu), with stroke onset less than two weeks exclusion criteria: death, serious sequela with motor, comprehensive or linguistic dysfunction, patients unwilling to join in, etiology of trauma, infective or tumor disease, patients with impaired cardiac, renal or liver function during admission-
predictive value of bone turnover markers during discontinuation with alendronate

Conditions: Osteoporosis

Summary: the study is a cohort study comprising 136 patients with osteoporosis stopping treatment with alendronate. the study will contribute with new knowledge about biochemical markers of bone turnover as predictors of bone loss after stopping treatment with alendronate.

background: osteoporosis increases the risk of fractures. alendronate reduces the risk of both vertebral- and hip fractures by approximately 50%. it has, however, become evident that long-term anti-resorptive may lead to serious side effects such as atypical femoral fractures or osteonecrosis of the jaw. the alendronate extension study (flex) showed that despite stopping treatment after five years the anti-fracture efficacy regarding non-vertebral and radiological vertebral fractures persists for an additional five years in patients with bone mineral density (bmd) t-score \> -2.5 at the femoral neck, no fractures during treatment, and no previous vertebral fracture. it is therefore now clinical practice, that treatment is discontinued after five years in patients that fulfil these criteria. based on the alendronate extension study it was assumed, that bone turnover monitored by biochemical markers would stay suppressed for years after stopping treatment, however, other studies have demonstrated that there is a great variability in the change in bone turnover markers seen after stopping treatment with alendronate in a real-life setting. aim: to investigate the predictive value of markers of bone turnover on bone loss 12 months after stopping alendronate therapy. methods: the study is a cohort study comprising 136 patients with osteoporosis stopping treatment with alendronate. perspectives: the study will contribute with new knowledge about biochemical markers of bone turnover as predictors of bone loss after stopping treatment with alendronate. it will thus be possible to identify patients who will experience a decrease in bmd during treatment break, and for this particular group of patients treatment can be re-initiated earlier so further loss of bone will be avoided. on the other hand, the biochemical markers of bone turnover could also shed light on who can tolerate treatment break, thereby avoid long-term treatment with alendronate, which may be associated with serious side effects. finally, the use of blood samples rather than dxa will reduce the use of x-rays.

Eligibility criteria:
inclusion criteria: * postmenopausal women (postmenopausal for at least two years) * men above 50 years * treatment for at least five years with alendronate * bmd t-score total hip \> -2.5 * bmd t-score lumbar spine (l1-l4) \> -4 exclusion criteria: * any low-energy fracture within the previous five years during alendronate treatment (not including fingers, toes, or skull) * low-energy vertebral fracture at any time * low-energy hip fracture at any time * ongoing treatment with glucocorticoids * metabolic bone disease * hormone replacement therapy * cancer * other conditions affecting bone metabolism

Keywords: bone turnover markers alendronate drug holiday
stereotactic radiosurgery (srs) for spine metastases

Conditions: Spinal Metastases

Summary: this study will evaluate the most effective radiation dose. patients will be randomized (like flipping a coin) to receive either low dose stereotactic radiotherapy (defined as "14 gy") or high dose stereotactic radiotherapy (defined as 18 gy).

this study will evaluate the pain control and the quality of life of patients with spinal metastases using stereotactic radiotherapy. stereotactic radiotherapy is referred to as "targeted therapy". it uses special equipment to position the patient and guide the focused beams of radiation toward the cancer and away from normal surrounding tissue. this higher dose technique may work better to kill cancer cells with fewer side effects than standard radiation therapy.

Eligibility criteria:
inclusion criteria: * signed informed consent. * age greater than or equal to 18 years old. * prior histologically-proven, non-hematogenous malignancy (specific exclusions are multiple myeloma and lymphoma). * radiographic evidence of one or two non-contiguous spinal metastases amenable to srs. * metastatic disease must be symptomatic (causing either pain or neurologic symptoms). * maximum tumor size less than or equal to 5 cm. * zubrod performance status of less than or equal to 3. * life expectancy of greater than or equal to 3 months. * women/men of childbearing potential must use effective contraception. exclusion criteria: * no prior radiation delivered to the involved area * no evidence of spinal instability requiring urgent surgical intervention. * no evidence of spinal cord compression requiring emergent surgical or radiotherapeutic intervention. * no plans for concomitant antineoplastic therapy (including standard fractionated rt, chemotherapy, biologic, vaccine therapy, or surgery) while on this protocol except at disease progression.concomitant is defined as within 3 days before or after radiosurgery. * no pregnant or lactating women. * no active systemic infection. * no evidence of myelopathy or cauda equina syndrome on clinical evaluation

Keywords: srs
cocoa flavanols in renal disease

Conditions: End Stage Renal Disease; Endothelial Dysfunction

Summary: purpose of the study is to characterize the potential acute and long-term improvement of dietary flavanols on vascular function in patients with end-stage renal disease (esrd). patients will twice daily receive either a flavanol-poor or a flavanol-rich drink. in a double blind, placebo-controlled crossover study the safety, efficacy and acute beneficial effects of flavanol ingestion will be assessed in 10 patients with esrd. in a 30 day long-term, double blind, placebo-controlled parallel study the chronic effects of dietary flavanols on vascular function in 52 patients with esrd will be evaluated.


Eligibility criteria:
inclusion criteria: * end stage renal disease * \>18 years * chronic intermittent hemodialysis exclusion criteria: * acute infection * acute renal failure * heart failure (nyha iv) * pregnancy * anuria
dame: induction of labor or waiting for suspicion fetal macrosomia

Conditions: Fetal Macrosomia

Summary: aim of the study :the major aim is to evaluate the effectiveness of the induction of labor in case of fetal macrosomia on the reduction of neonatal traumatism risk. the secondary aims are to evaluate maternal morbidity and the risk of caesarean in case of induction of labor, compared to a spontaneous labor.

a clinical trial multicentric randomized controlled will be organized. a total of 1000 women will be recruited between 36 and 38 weeks of amenorrhoea (gw) if the pregnancy is single, in cephalic presentation and the fetus is estimated macrosomic for the gestational age (\> 90e percentile clinically and \>95° percentile sonographically).all agreeing patients will be randomized in one of the two following groups: - 1. induction of labor between 37+0 and 38+6 gw and within 3 day after the randomization. - 2. expectancy until the spontaneous beginning of labor or up to 41 gw.the measurement of principal exit is the neonatal traumatism (criterion composite associating: dystocia of the shoulders, fractures osseous, paralysis/paresis of the plexus brachial or intracerebral haemorrhage).the secondary criteria are neonatal asphyxiation (arterial ph \< 7.10 or apgar \< 7 to 5 minutes), the maternal traumatism (tear of 3rd or 4th degree) and the caesarean. the long-term after-effects for the mother and her child will be also evaluated

Eligibility criteria:
inclusion criteria: * agreed women sonographic estimation of begin of pregnancy \<20gw single pregnancy in cephalic presentation macrosomic fetus : * clinical estimation : 36gw : ≥3350g or 34cm 37gw : ≥3550gor34cm 38gw : ≥3750g or 35cm * sonographic estimation : 36gw : ≥ 3500g 37gw : ≥ 3700g 38gw : ≥ 3900g exclusion criteria: * typical diabetes i or typifies ii or diabetes gestational treated by insulin. * antecedents of tear of the anal sphincter or severe urinary or faecal presence of an incontinence. * antecedent of dystocia of the shoulders or neonatal traumatism. * antecedents of caesarian or uterine scar. * contraindication in the release of the work or in the childbirth by low way.

Keywords: fetal macrosomia neonatal traumatism maternal morbidity
glp_1 ra ultrasound study

Conditions: Glucagon Like Peptide-1 (GLP-1; Delayed Gastric Emptying; Risk of Aspiration; Diabetes; Morbid Obesity

Summary: the purpose of the study is to determine whether patients taking glp-1 ras have increased residual (left behind), gastric (stomach), contents due to delayed gastric emptying when following standard preoperative fasting guidelines.


Eligibility criteria:
inclusion criteria: * body mass index over 35 * type 2 diabetes * currently taking glp01 ra agonist (for glp 1 group) * not taking glp-1 ra agonist (for control group) exclusion criteria: * diagnosis of gastroparesis * patient refusal to participate * previous gastric bypass or any other gastric surgery * currently on peritoneal dialysis * abdominal pathology * gastro-intestinal obstruction * pregnancy

Keywords: glp-1 glucagon like peptide 1 aspiration gastric empty
acceptability, representations and experiences of the covid-19 pandemic

Conditions: Aging

Summary: the "arecovid" project is a comprehensive sociological study of what is being played out in organizational terms in the face of the covid-19 pandemic. through quantitative methods (questionnaires) and qualitative methods (semi-directive interviews), we would understand the essential views of the populations concerned by covid-19, but also that of actors taking care of vulnerable elderly non-covid. special attention will be paid to the care pathway of elderly people with and without the virus, in a health system in full reorganization. we will try to understand the needs and experiences of all health actors (hospital/city) involved in covid-19 and the experience of confinement and the covid-19 of the elderly living at home, in order to reflect on a possible improvement in the health response of elderly people in the event of an epidemic health crisis.

understand the needs and experiences of all health actors (hospital/city) involved in covid-19 and the experience of confinement and the covid-19 of the elderly living at home

Eligibility criteria:
inclusion criteria: * for older people : minimum age : 65 years * for caregivers : works in gerontology exclusion criteria: * person with a neurological disease * person under guardianship or curatorship

Keywords: covid-19 caregivers older ageism public health hospital
derm us and eu validation study

Conditions: Malignant Skin Melanoma T0; Basal Cell Carcinoma; Squamous Cell Carcinoma

Summary: this study aims establish the effectiveness of image analysing algorithm (derm) to identify melanoma, squamous cell carcinoma (scc) and basal cell carcinoma (bcc) when used to analyse dermoscopic images of skin lesions within the us and european population.


Eligibility criteria:
inclusion criteria: * willing and able to give informed consent for participation in the study, * male or female, aged 18 years or above, * have at least one suitable skin lesion that will be biopsied due to a suspicion of skin cancer, to be suitable for inclusion, a skin lesion must not have any of the following limitations: located on an anatomical site of different skin structure: palms of hands or soles of feet (acral lesion), mucosal surfaces (lips and eyes) or under nail (ungal lesion), a diameter greater than the diameter of the dermoscopic lenses, located on an anatomical site unsuitable for photographing, including on surface of genitals and hair-bearing areas, has been previously biopsied, excised, treated or otherwise traumatised, located in an area of visible scarring or tattooing. - in the investigator's opinion, able and willing to comply with all study requirements. exclusion criteria: * any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
the pandemic stress vaccine: a resource to enhance the resilience of healthcare workers facing an infectious outbreak

Conditions: Psychological Stress

Summary: the purpose of this study is to determine the effects of an interactive, computerized learning resource designed to increase resilience in hospital-based health care workers preparing for an influenza pandemic. the effects of the learning resource will be compared to a non-interactive learning resource condition and a control condition. it is hypothesized that (a) online pandemic-related education reduces absenteeism and interpersonal problems for healthcare workers (hcws), and improves their pandemic self-efficacy in the short and long-term, and (b) an interactive format for online education is necessary for its benefits.


Eligibility criteria:
inclusion criteria: * employee or professional staff of a hospital exclusion criteria: * unable to read and write english

Keywords: health personnel communicable diseases stress, psychological resilience, psychological disaster planning education online
a study of efficacy and safety of ustekinumab in patients with primary biliary cirrhosis (pbc) who had an inadequate response to ursodeoxycholic acid

Conditions: Primary Biliary Cirrhosis

Summary: the purpose of this study is to evaluate the efficacy and safety of ustekinumab in patients with primary biliary cirrhosis who had an inadequate response to ursodeoxycholic acid.

this is a multi-center, randomized (treatment will be assigned by chance), placebo-controlled (an inactive substance will be compared with the test drug to see whether the drug has a real effect), parallel-group (two or more groups of patients will receive different treatments) study that will consist of two parts. part 1 will be an open-label (all participants will know the identity of the treatment) proof-of-concept study. part 2 will be contingent on the results of part 1 and will be double-blind (investigators and patients will not know what treatment is being given) and will evaluate the efficacy and safety of ustekinumab in patients with primary biliary cirrhosis (pbc) who had an inadequate response to ursodeoxycholic acid. the duration of participation in the study for an individual participant may be up to 216 weeks. patient safety will be monitored. part 1: ustekinumab, 90mg subcutaneous (sc) at weeks 0 and 4 and every 8 weeks through week 20; part 2: depending on part 1 results, either (ustekinumab 90mg or 45mg or placebo) or (ustekinumab 90mg or 180mg or placebo) sc at weeks 0 and 4 and every 8 weeks through week 20; long-term extension (including part 1 and part 2): beginning at week 28, every 8 weeks with initially assigned dose until the extension dose has been selected; then every 8 weeks through week 196 with the selected dose.

Eligibility criteria:
inclusion criteria: * have proven or are likely to have primary biliary cirrhosis (pbc) * be on a stable dose of ursodeoxycholic acid for at least 6 months prior to week 0 * have screening alkaline phosphatase (alp) level \> 1.67 uln (the upper limit of normal) * have screening laboratory test results within protocol-specified limits * have no history of latent or active tuberculosis (tb) prior to screening and no signs or symptoms suggestive of active tb upon medical history and/or physical examination. exclusion criteria: * has history of gastrointestinal bleeding, secondary to portal hypertension, hepatic encephalopathy, or ascites requiring treatment with diuretics * has a screening direct bilirubin \> 1.0 mg/dl * has a previous liver histology with a diagnosis of steatohepatitis or has a high risk of nonalcoholic steatohepatitis * has a previous liver histology with a diagnosis of chronic autoimmune hepatitis or has a high risk of autoimmune hepatitis overlap syndrome * testing positive for surface antigen (hbsag+), regardless of the results of other hepatitis b tests * have used colchicine, methotrexate (mtx), azathioprine (aza), or systemic corticosteroids within 3 months prior to the first administration of study drug.

Keywords: diseases [c] - digestive system diseases [c06] primary biliary cirrhosis ursodeoxycholic acid (udca) stelara ustekinumab
tlk286 (telcyta) in combination with carboplatin (paraplatin) versus doxil in platinum refractory or resistant ovarian cancer

Conditions: Ovarian Neoplasms

Summary: the purpose of this research study is to determine if tlk286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer, that is refractory or resistant to platinum chemotherapy.


Eligibility criteria:
inclusion criteria: * are a woman 18 years of age or older * have histologically or cytologically confirmed epithelial cancer of the ovary or fallopian tube, or primary peritoneal cancer * have platinum refractory or resistant cancer * measurable disease according to radiographic recist criteria with documented tumor progression exclusion criteria: * had treatment with first-line chemotherapy other than platinum-based regimens (carboplatin or cisplatin) * have clinically significant cardiac disease * have any sign of intestinal obstruction interfering with nutrition at the time of study entry * are pregnant or lactating * had prior treatment with liposomal doxorubicin for ovarian cancer * had prior treatment with tlk286

Keywords: ovary
respiratory complications of operated esophageal atresia in children

Conditions: Esophageal Atresia

Summary: the respiratory complications of esophageal atresia have already been identified. they are mainly related to tracheomalacia linked to the esophageal malformation, and are aggravated by frequently associated gastroesophageal reflux. in this context, symptoms of asthma (or bronchial hyperreactivity) occur more frequently than in the general population and persist into adulthood. their pathogenesis is still poorly understood and is the subject of much discussion. the therapeutic management of these respiratory complications, poorly codified, remains very heterogeneous from one center to another. in france, the summary of knowledge is updated by the reference center for chronic and malformative diseases of the esophagus.


Eligibility criteria:
inclusion criteria: * child aged 1 to 12 years old * child operated on for esophageal atresia between 01/01/2010 and 31/12/2020 and followed up at the university hospitals of strasbourg * child who has not expressed, after being informed, his opposition to the reuse of his data for the purposes of this research * parental authority having not expressed, after being informed, their opposition to the reuse of their child's data for the purposes of this research. exclusion criteria: subject and/or parental authority having expressed their opposition to participating in the study

Keywords: esophageal atresia esophageal malformation gastroesophageal reflux asthma bronchial hyperreactivity
rate ventricular control therapy in patients with permanent atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the investigators hypothesized that very lenient rate control is not inferior to strict or lenient rate control assessed by implantable continuous ecg monitor for preventing cardiovascular hospitalization and mortality in patients with long-standing persistent or permanent atrial fibrillation


Eligibility criteria:
inclusion criteria: * long-standing persistent or permanent atrial fibrillation * mean resting heart rate \> 80 beats per minute with or without rate control medication * age \< 70 years old * constant use of anticoagulation therapy exclusion criteria: * paroxysmal or persistent atrial fibrillation * non-stable heart failure or \> iii nyha fc * indications for ipg/crt/icd * thyroid dysfunction * inability to walk or bike.

Keywords: rate control ilr
study of in vivo and in vitro transcriptomic and proteomic signatures in unhereditary ichtyosis

Conditions: Autosomal Recessive Congenital Ichthyosis; Epidermolytic Ichthyosis

Summary: the goal of this study is to identify important biological pathways involved in a variety of ichtyosis, using transcriptomic and proteomic techniques, with the aim of guiding the development of new therapeutis.


Eligibility criteria:
inclusion criteria: * aged 15-80 years old * having an arci or ei, confirmed by a molecular diagnosis of a mutation in at least one of the following genes: tgm1, alox12b, nipal4, abca12, keratin 1 and keratin 10) * having stopped all topical treatments in at least 1% of the total body surface (equivalent to one palm of the hand of the patient), at least 8 days before the skin biopsy (which will be performed on this untreated area). * patients having a molecular diagnostic of genetic ichtyosis * no contraindication to skin biopsy * health insurance coverage * signature of written consent exclusion criteria: * aged less than 15 of over 80 years old * ichtyosis without a molecular confirmed diagnosis or with a different diagnosis * history, in the 8 previous days, of any topical treatment on the area intended for the skin biopsy. * no health insurance coverage * pregnant or breastfeeding woman * patient under guardianship or curatorship * patient under state medical assistance (ame)